May 18, 2026Financings for May 18, 2026Biopharma and med-tech companies raising money in public or private financings, including: Imperative Care.
May 18, 2026By Tamra SamiDegron closes $40M series A to advance molecular glue degradersDegron Therapeutics Inc. closed a $40 million series A extension round that will see the company advance its molecular glue degraders targeting previously undruggable or insufficiently drugged proteins.
May 15, 2026Financings for May 15, 2026Biopharma and med-tech companies raising money in public or private financings, including: Armata, Bluewind Medical, Butterfly, Capehaven, Create Medicines, Degron, EBT, Mezzion, Ninamed, Urologic Health, Uromems, Xortx.
